Notes: May 3, 2019, Adynxx, Inc., formerly known as Alliqua Biomedical, Inc., completed a business combination with privately-held Adynxx, Inc. Also, on May 3, 2019, in connection with, and immediately prior to the completion of the Merger, the company effected a reverse stock split at a ratio of one new share for every six shares of common stock outstanding, or the Reverse Stock Split, and immediately following the Merger, they company changed its name to Adynxx, Inc. Following the completion of the Merger, the business conducted by Private Adynxx became primarily the business conducted by us, which is the development of novel, disease-modifying pharmaceutical product candidates for the treatment of pain and inflammation. The trading symbol also changed on that date from ALQA to ADYX. The common stock is represented by a new CUSIP number 00784D 103.